Half-year report · Q2
4361.TEDINET S100WBL8
Period2024-12-01 → 2025-05-31
Filed2025-07-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.3bn | 2024-12-01 → 2025-05-31 | Cons. | Net sales |
| Revenue | ¥8.9bn | 2023-12-01 → 2024-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.2bn | 2023-12-01 → 2024-05-31 | Cons. | Net sales |
| Operating income | ¥199m | 2024-12-01 → 2025-05-31 | Cons. | Operating income |
| Operating income | ¥202m | 2023-12-01 → 2024-05-31 | Cons. | Operating income |
| Ordinary income | ¥183m | 2024-12-01 → 2025-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥390m | 2023-12-01 → 2024-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥212m | 2023-12-01 → 2024-05-31 | Cons. | Ordinary income |
| Profit before tax | ¥183m | 2024-12-01 → 2025-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥252m | 2023-12-01 → 2024-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥135m | 2024-12-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥336m | 2023-12-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥193m | 2023-12-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥135m | 2024-12-01 → 2025-05-31 | Cons. | Profit loss |
| Net income | ¥193m | 2023-12-01 → 2024-05-31 | Cons. | Profit loss |
| Total assets | ¥8.8bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥8.5bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥8.0bn | at 2024-05-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.8bn | at 2025-05-31 | Cons. | Liabilities |
| Total liabilities | ¥5.6bn | at 2024-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥2.9bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥2.9bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.7bn | at 2024-05-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥745m | at 2024-11-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.3bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥745m | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥947m | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2023-11-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥566m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥143m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥90m | 2023-12-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥216m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥305m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥96m | 2023-12-01 → 2024-05-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥187m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥139m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥101m | 2023-12-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥110.52 | 2024-12-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥276.22 | 2023-12-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥158.38 | 2023-12-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 33.5% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.8% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.2% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2024-12-01 → 2025-05-31 | ¥184m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue | 2024-12-01 → 2025-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue external | 2024-12-01 → 2025-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | segment profit | 2024-12-01 → 2025-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-12-01 → 2025-05-31 | ¥199m |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2023-12-01 → 2024-05-31 | ¥4.2bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2023-12-01 → 2024-05-31 | ¥4.2bn |
| jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2023-12-01 → 2024-05-31 | ¥187m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue | 2023-12-01 → 2024-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | revenue external | 2023-12-01 → 2024-05-31 | ¥19m |
| jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segment | segment profit | 2023-12-01 → 2024-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-12-01 → 2024-05-31 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-12-01 → 2024-05-31 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-12-01 → 2024-05-31 | ¥202m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 484
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 370000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 300000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -401668000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -31668000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -8861000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -8861000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -60433000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -72492000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -100963000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 186978000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 10749000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | -8544000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -96838000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 528668000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1043816000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 744643000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 946977000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 1273312000 | JPY |
| Employee payrolls and allowances sga | Prior1YTDDuration | 143944000 | JPY |
| Employee payrolls and allowances sga | CurrentYTDDuration | 137164000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 7328000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 22673000 | JPY |
| Provision for directors bonuses sga | Prior1YTDDuration | 5700000 | JPY |
| Provision for directors bonuses sga | CurrentYTDDuration | 4650000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 5118000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 10953000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 120269000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 127235000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4229080000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 19197000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 4248278000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 4248278000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4229080000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 19197000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 4248278000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 4248278000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 187025000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 15393000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 202418000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 202418000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 4294861000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E01006-000RealEstateLeasingReportableSegmentMember | 19197000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |